Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2018 ASCO Annual Meeting!


Session: Patient and Survivor Care

Type: Poster Session

Time: Monday June 4, 1:15 PM to 4:45 PM

Location: Hall A

Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.

Sub-category:
Late and Long-Term Effects

Category:
Patient and Survivor Care

Meeting:
2018 ASCO Annual Meeting

Abstract No:
10058

Poster Board Number:
Poster Session (Board #46)

Citation:
J Clin Oncol 36, 2018 (suppl; abstr 10058)

Author(s): Omar El Charif, Zepeng Mu, Eric R Gamazon, Paul C Dinh, Shirin Ardeshirrouhanifard, Patrick O. Monahan, Darren R. Feldman, Lawrence H. Einhorn, Robert James Hamilton, David J. Vaughn, Neil E. Martin, Chunkit Fung, Sophie D. Fossa, Lois B. Travis, M. Eileen Dolan; The University of Chicago, Chicago, IL; Vanderbilt University, Nashville, TN; Indiana University School of Medicine, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, New York, NY; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Dana-Farber Cancer Institute/ Brigham and Women's Hospital, Boston, MA; University of Rochester Medical Center, Rochester, NY; Oslo University Hospital, University of Oslo, Oslo, Norway; University of Chicago, Chicago, IL

Abstract Disclosures

Abstract:

Background: Platinum (Pt) is detectable for years after cisplatin treatment completion, but few studies have examined the extent of long-term exposure to Pt and associated co-morbidities. Methods: Eligible testicular cancer survivors (TCS, n = 633) given 300 or 400 ± 15 mg/m2 cisplatin underwent lab tests and extensive audiometry, and completed questionnaires at follow-up (median 5 y, range 1-35). Since subject-level PK parameters cannot be estimated in cross-sectional designs, we regressed log(Pt) on dose and follow-up time in the entire cohort. Each subject’s PK trait was defined as the deviation from the average concentration-time curve (the residual). High values indicate Pt levels exceeding the expected value, i.e. slower elimination. The Pt reference interval (RI) used (central 95% of 147 non-Pt exposed patients) was 8-47 ng/L (JALM 2016; 1:2, 143). Linear regression at α = 0.05 was used for associations with co-morbidities. Hearing loss was quantified as the geometric mean of thresholds: 4-12 kHz (JCO 2016; 34, 2712). Sensory neuropathy was self-reported using EORTC-CIPN20. Cardiovascular (CV) burden was defined as angina, angioplasty, stroke, DVT, PE, CAD, and/or MI > 1 month after therapy. Serum Pt, LDL, HDL, and creatinine (used to estimate creatinine clearance [CrCl] with the Cockroft-Gault formula) were measured. Results: Only 35 TCS (5.6%) were within the RI (median follow-up for this group: 20 y, range: 10-35). The estimated time to reach RI upper limit was 18 and 21 y after 300 and 400 mg/m2 cisplatin respectively (time to RI median: 46 and 57 y). The Pt PK phenotype was strongly negatively associated with CrCl (p < 10-9), and positively associated with age (p < 10-8), neuropathy (p = 0.002; age-adjusted p = 0.04), and HDL (age-adjusted p < 0.001). When adjusted for age, no associations were apparent with LDL, CV burden, or hearing loss. Conclusions: Circulating Pt persists for decades and may contribute to adverse outcomes. We previously showed that hearing loss, but not neuropathy, is associated with cumulative cisplatin dose. In conjunction with our findings here, this suggests differential kinetics of ototoxicity and neurotoxicity.

 
Other Abstracts in this Sub-Category:

 

1. Impact of cancer on employment and finances in young adult (YA) survivors.

Meeting: 2018 ASCO Annual Meeting Abstract No: 10013 First Author: Tyler Garrett Ketterl
Category: Patient and Survivor Care - Late and Long-Term Effects

 

2. Predictors of long-term follow-up care (LTFU) among survivors of adolescent and young adult (AYA) cancers: A population-based study in the IMPACT cohort.

Meeting: 2018 ASCO Annual Meeting Abstract No: 10014 First Author: Dalia Kagramanov
Category: Patient and Survivor Care - Late and Long-Term Effects

 

3. Risk of chronic comorbidities in survivors of adolescent and young adult cancer (AYA).

Meeting: 2018 ASCO Annual Meeting Abstract No: 10015 First Author: Chun Chao
Category: Patient and Survivor Care - Late and Long-Term Effects

 

More...